Skip to main content

Actuate Therapeutics Inc(ACTU-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Actuate Therapeutics Inc

1751 RIVER RUN SUITE 400
FORT WORTH TX 76107 USA
P: 817-887-8455
https://actuatetherapeutics.com

Profile

Actuate Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers. The company's lead product includes elraglusib. Actuate Therapeutics Inc. is based in FORT WORTH, Texas.

Key Executives

NameTitle
Paul J. LytleCFO/Chief Accounting Officer
Andrew P. MazarCOO
Daniel M. SchmittCEO/Director/President

More from The Globe

The time may be right to focus on neglected stocks
Robert Tattersall
Small caps to watch: Dynacor Group, Spectral Medical, Pizza Pizza and more
After a volatile weekend with 25% tariffs levied (10% on oil and gas) on all Canadian products going into the United States, the S&P TSX Composite Index shows market reaction on Feb 3, 2025. (Fred Lum/The Globe and Mail)
Bullish on NextEra Energy Inc.
Monica Rizk
number cruncher
Ten transportation stocks to watch as oil prices rise
For Number Cruncher column in Globe Investor/ROB only.
The most oversold and overbought stocks on the TSX
The Bay Street Financial District is shown with the Canadian flag in Toronto on Friday, August 5, 2022.
Monday’s analyst upgrades and downgrades
The Bay Street Financial District is shown with the Canadian flag in Toronto on Friday, August 5, 2022. THE CANADIAN PRESS/Nathan Denette
Insider Report: Chair sells $5-million from this stock yielding 5.8% that’s doubled in under a year
The Bay Street Financial District is shown with the Canadian flag in Toronto on Friday, August 5, 2022. THE CANADIAN PRESS/Nathan Denette
Canaccord reworks U.S. leadership in wake of regulatory settlement
The logo for Canaccord Genuity is shown in Toronto on Wednesday, March 8, 2023. THE CANADIAN PRESS/Staff

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Financial data provided by Zacks Investment Research.